An observational study in Sarcoma, Soft Tissue and Retroperitoneal Sarcoma, sponsored by Heidelberg University. Recruiting at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Heidelberg University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Sarcoma with a site in Germany — 21 open to participants now, 30 under way, 3 of them phase 3. Sarcoma · Germany.
Among the 103 studies in Sarcoma with a site in Germany, this one is the 11th largest by planned enrollment of the 19 observational ones that give a count, is one of 6 that started in 2025, is one of 19 observational ones, reaches primary completion later than 9 of the 29 other live ones, and was the 99th registered.
1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →21 of the 103 studies in Sarcoma with a site in Germany are open now. Recruiting first, the newest first:
Universität Duisburg-Essen · Sites in Germany
Ages 15+
Technical University of Munich · Sites in Germany
Technische Universität Dresden · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in Germany, United States, Canada and 4 more countries
Ages 18+
Adcendo ApS · Sites in Germany, United States, Belgium and 2 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 44 · Phase 3 19
First in 1995; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is close to the median of 120 across 220 observational studies indexed under Sarcoma.
Median enrollment 103 across the 83 interventional studies, 130 across the 19 observational. Of the 69 that completed or were terminated, 21 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 103 have an industry lead sponsor. The 10 most frequent:
Heidelberg University is the lead sponsor of 287 studies on the registry; 18 are open to participants now.
Heidelberg University has 5 studies filed under Sarcoma — fewer than ten, so there is no comparison to draw.
5 of the studies in Sarcoma with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07939139Technical University of MunichShadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards | 2027-01-31 |
| NCT05492682Valo Therapeutics OySTART: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | 2027-04-30 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
| NCT07148193Technische Universität DresdenQuality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+) | 2027-09 |
| NCT06743958Technical University of MunichPrehabilitation in Childhood Soft Tissue or Bone Sarcomas | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 103 studies in Sarcoma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
COLOSARC-Q is a multicenter study with the objective of providing an up-to-date assessment of colorectal resections and reconstruction techniques in the context of multivisceral resections for retroperitoneal sarcomas, as well as colorectal surgery-associated complications and their impact on patients' quality of life.
In multivisceral resections involving the colon and rectum, the primary aim is to achieve complete resection and preserve organ function. However, multivisceral resections have a high risk of perioperative morbidity including anastomotic leakage. The proposed project aims to determine the number of primary anastomoses, their insufficiency rates, and the fraction of patients with primary and secondary stomas. In addition, the patients' quality of life after multivisceral sarcoma resection is to be recorded using standardized surveys.
The analysis has the potential to facilitate intraoperative decision-making for colorectal resections in the context of multivisceral resections.
The primary goal of retroperitoneal sarcoma surgery is to achieve complete resection. The resection of retroperitoneal sarcomas (RPS) usually involves the removal of parts of the colon. While there is good data on surgical principles and postoperative complications of multivisceral resections in RPS as a whole (1, 2), there is little evidence on the frequency of temporary or permanent stomas and complications associated with intestinal surgery (e.g., number of anastomotic leackages in relation to the number of intestinal anastomoses performed) and their impact on the quality of life of those affected.
The COLOSARC-Q study is a multicenter, non-interventional study with the aim of documenting
COLOSARC-Q has the potential to improve preoperative participatory decision-making and intraoperative strategy in colorectal resections as part of multivisceral resections in order to reduce complication rates and develop surgical strategies tailored to specific patient needs.
Patients with primary, retroperitoneal sarcomas who underwent surgery with colorectal resection at DKG-certified sarcoma centers or hospitals in Germany and Switzerland that meet certification-equivalent criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with primary retroperitoneal sarcomas who underwent surgery with colorectal resection at DKG-certified sarcoma centers or hospitals in Germany and Switzerland that meet certification-equivalent criteria
Evaluation of resection and reconstruction procedures of the colon and rectum in the context of multivisceral resections of retroperitoneal sarcomas
Description of the surgical procedure, e.g. righ hemicolectomy with primary anastomosis
Time frame: immediately after the surgery
Postoperative complications associated with resections and reconstructions of the bowel
Evaluation of postoperative complications associated with resections and reconstructions of the bowel during and after multivisceral resections of retroperitoneal sarcomas (Comprehensive Complication Index (CCI), up to 90 days postoperatively)
Time frame: up to 90 days after surgery
Assessment of quality of life after colorectal resections in the context of RPS resections
Assessment of quality of life after using the EORTC QLQ - C30 (Version 3.0) questionnaires)
Time frame: through study completion, an average of 1 year
Assessment of changes in bowel function after resection of retroperitoneal sarcomas
Assessment of the bowel function using the EORTC QLQ - CR29 questionnaire
Time frame: through study completion, an average of 1 year
Identification of problems and needs of RPS patients
Identification of problems and needs of RPS patients who have undergone resection and reconstruction of the colon, e.g. with regard to education, home care, bowel function, stoma care, rehabilitation measures and therapy intensity and sequence
Time frame: through study completion, an average of 1 year
Determination of patient-, tumor- and treatment-related factors influencing the above-mentioned primary and secondary study objectives
Determination of the influence of the following patient-, tumor- and treatment-related factors on the above-mentioned primary and secondary study objectives: * Gender * age * Body mass index (BMI) * Malnutrition (serum albumin preoperatively) * Concomitant diseases (e.g. diabetes mellitus, coronary heart disease) * Previous abdominal surgery * Size, localization (left/right), grading and histological subtype of the RPS * Neoadjuvant therapies (radiotherapy and/or chemotherapy) * Operation time * Intraoperative blood loss * Extent of the surgical procedure
Time frame: through study completion, an average of 1 year
Plan to share: No
Ran from Jan 2025 to primary completion in Jun 2026, 17 months.
Of 88 non-industry observational studies under Sarcoma, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 294. This study's 17 months is below that.
Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 42 and three quarters within 294.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.